随着全球肥胖治疗市场竞争加剧,诺和诺德正通过多项合作强化其领导地位,尤其在口服药物领域。最新动态显示,诺和诺德宣布与Deep Apple Therapeutics达成8.12亿美元合作协议,共同开发针对肥胖及心血管代谢疾病的口服小分子药物。如此重金投入,背后是对口服小分子药物巨大潜力的坚定押注。尽管其核心靶点——一种非肠促胰岛素 GPCR,目前仍被“秘而不宣”,仅以“新型”一词示人,但这无疑已成功...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.